Compare SCVL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCVL | CTNM |
|---|---|---|
| Founded | 1978 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.1M | 480.5M |
| IPO Year | 1994 | 2024 |
| Metric | SCVL | CTNM |
|---|---|---|
| Price | $18.01 | $13.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 513.7K | 281.8K |
| Earning Date | 05-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $1,135,324,000.00 | N/A |
| Revenue This Year | $1.64 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | $9.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.04 | $3.35 |
| 52 Week High | $26.54 | $16.33 |
| Indicator | SCVL | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 48.12 |
| Support Level | $16.80 | $10.17 |
| Resistance Level | $18.37 | $13.18 |
| Average True Range (ATR) | 0.88 | 0.80 |
| MACD | 0.30 | 0.04 |
| Stochastic Oscillator | 95.25 | 42.79 |
Shoe Carnival Inc is a family footwear retailer that offers a broad assortment of dress, casual, and athletic footwear for men, women, and children with an emphasis on national name brands such as Nike, Skechers, Adidas, Puma, HEYDUDE, Converse, Vans, and Crocs. The company operates its business as one reportable segment based on the similar nature of products sold; merchandising, distribution, and marketing processes involved; target customers; and economic characteristics of stores and e-commerce platforms. Its bricks-first, omnichannel approach provides customers easy access to a wide assortment of branded footwear for work, athletics, daily activities, and special events via a choice of delivery channels.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.